<SEC-DOCUMENT>0001641172-25-026294.txt : 20250902
<SEC-HEADER>0001641172-25-026294.hdr.sgml : 20250902
<ACCEPTANCE-DATETIME>20250902215046
ACCESSION NUMBER:		0001641172-25-026294
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250902
DATE AS OF CHANGE:		20250902

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DSS, INC.
		CENTRAL INDEX KEY:			0000771999
		STANDARD INDUSTRIAL CLASSIFICATION:	PAPERBOARD CONTAINERS & BOXES [2650]
		ORGANIZATION NAME:           	04 Manufacturing
		EIN:				161229730
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-50256
		FILM NUMBER:		251287625

	BUSINESS ADDRESS:	
		STREET 1:		275 WIREGRASS PKWY
		CITY:			WEST HENRIETTA
		STATE:			NY
		ZIP:			14586
		BUSINESS PHONE:		585 232 1500

	MAIL ADDRESS:	
		STREET 1:		275 WIREGRASS PKWY
		CITY:			WEST HENRIETTA
		STATE:			NY
		ZIP:			14586

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DOCUMENT SECURITY SYSTEMS INC
		DATE OF NAME CHANGE:	20030326

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEW SKY COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THOROUGHBREDS USA INC
		DATE OF NAME CHANGE:	19861118

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chan Heng Fai Ambrose
		CENTRAL INDEX KEY:			0001261725
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		2601 INSLAND PLACE TOWER
		STREET 2:		510 KINGS RD N POINT
		CITY:			HONG KONG
		STATE:			K3
		ZIP:			999999999

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHAN FAI
		DATE OF NAME CHANGE:	20030828
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001641172-25-025258</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Chan Heng Fai Ambrose -->
          <cik>0001261725</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>22</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.02 per share</securitiesClassTitle>
      <dateOfEvent>08/28/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0000771999</issuerCIK>
        <issuerCUSIP>26253C201</issuerCUSIP>
        <issuerName>DSS, INC.</issuerName>
        <address>
          <com:street1>275 Wiregrass Pkwy</com:street1>
          <com:city>West Henrietta</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>14586</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Heng Fai Ambrose Chan</personName>
          <personPhoneNum>011 65 6333 9181</personPhoneNum>
          <personAddress>
            <com:street1>9 Temasek Boulevard #16-04, Suntec Tower</com:street1>
            <com:city>Singapore</com:city>
            <com:stateOrCountry>U0</com:stateOrCountry>
            <com:zipCode>038989</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001261725</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Heng Fai Ambrose Chan</reportingPersonName>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U0</citizenshipOrOrganization>
        <soleVotingPower>6599380.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>6599380.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>6599380.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>68.2</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>(1) The beneficial ownership of Heng Fai Ambrose Chan includes 6,599,380 shares of the Issuer's common stock, consisting of (a) 1,002,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Ambrose Chan; (b) 1,184,475 shares of common stock held by Heng Fai Ambrose Chan directly; (c) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited; (d) 2,581,268 shares of common stock and a convertible promissory note in the amount of $500,000 held by Alset Inc. and initially convertible into 581,395 shares of the Issuer's common stock; and (e) 1,068,309 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc. (2) Based on 9,092,518 shares of the common stock of the Issuer outstanding as of September 2, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Alset Inc.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>TX</citizenshipOrOrganization>
        <soleVotingPower>4542606.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>4542606.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>4542606.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>47.0</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>(1) Includes 2,581,268 shares of common stock and a convertible promissory note in the amount of $500,000 held by Alset Inc. and initially convertible into 581,395 shares of the Issuer's common stock; 311,634 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited; and 1,068,309 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc. (2) Based on 9,092,518 shares of the common stock of the Issuer outstanding as of September 2, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Global Biomedical Pte. Ltd.</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U0</citizenshipOrOrganization>
        <soleVotingPower>311634.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>311634.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>311634.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>3.4</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Based on 9,092,518 shares of the common stock of the Issuer outstanding as of September 2, 2025.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Alset International Limited</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>U0</citizenshipOrOrganization>
        <soleVotingPower>1379943.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>1379943.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>1379943.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>15.2</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Based on 9,092,518 shares of the common stock of the Issuer outstanding as of September 2, 2025.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.02 per share</securityTitle>
        <issuerName>DSS, INC.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>275 Wiregrass Pkwy</com:street1>
          <com:city>West Henrietta</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>14586</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>Heng Fai Ambrose Chan</filingPersonName>
        <principalBusinessAddress>c/o Alset International Limited, 9 Temasek Boulevard #16-04, Suntec Tower Two, Singapore 038987</principalBusinessAddress>
        <principalJob>Chairman and Chief Executive Officer, Alset International Limited, 9 Temasek Boulevard #16-04, Suntec Tower Two, Singapore 038987</principalJob>
        <citizenship>Singapore</citizenship>
      </item2>
      <item3>
        <fundsSource>On August 20, 2025, the Issuer issued a convertible promissory note to Alset Inc. in the amount of $500,000.00. Under the terms of the convertible promissory note, Alset Inc. may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of $0.86 per share, or if while the convertible promissory note is outstanding, the Issuer sells or issues any other convertible instruments on terms that differ from the convertible promissory note, the holder may elect to exchange the convertible promissory note for such convertible instrument based on the convertible promissory note's principal balance plus any accrued but unpaid interest.

On August 28, 2025, Mr. Chan sold 130,679 shares of the Issuer's common stock at an average sale price of $1.3475. The shares were sold in multiple trades at prices ranging between $1.23 and $1.565. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>On August 20, 2025, the Issuer issued a convertible promissory note to Alset Inc. in the amount of $500,000.00. Under the terms of the convertible promissory note, Alset Inc. may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of $0.86 per share, or if while the convertible promissory note is outstanding, the Issuer sells or issues any other convertible instruments on terms that differ from the convertible promissory note, the holder may elect to exchange the convertible promissory note for such convertible instrument based on the convertible promissory note's principal balance plus any accrued but unpaid interest. This Amendment No. 22 to Schedule 13D/A amends Amendment No. 21, filed with the SEC on August 22, 2025, in order to provide additional clarity to the terms of the convertible promissory note.

On August 28, 2025, Mr. Chan sold 130,679 shares of the Issuer's common stock at an average sale price of $1.3475. The shares were sold in multiple trades at prices ranging between $1.23 and $1.565. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Heng Fai Ambrose Chan: 6,599,380, 68.2% Alset Inc.: 4,542,606, 47.0% Global Biomedical Pte. Ltd.: 311,634, 3.4% Alset International Limited: 1,379,943, 15.2%</percentageOfClassSecurities>
        <numberOfShares>Heng Fai Ambrose Chan: 6,164,664 Alset Inc.: 4,542,606 Global Biomedical Pte. Ltd.: 311,634 Alset International Limited: 1,379,943</numberOfShares>
        <transactionDesc>None.</transactionDesc>
      </item5>
      <item7>
        <filedExhibits>Joint Filing Agreement between Heng Fai Chan, Global Biomedical Pte. Ltd. and Alset Inc., incorporated by reference to Amendment No. 13 to the Schedule 13D filed on September 20, 2021.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Heng Fai Ambrose Chan</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Heng Fai Ambrose Chan</signature>
          <title>Heng Fai Ambrose Chan, an Individual</title>
          <date>09/02/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Alset Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Heng Fai Ambrose Chan</signature>
          <title>Heng Fai Ambrose Chan, Chief Executive Officer, Alset Inc.</title>
          <date>09/02/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Global Biomedical Pte. Ltd.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Heng Fai Ambrose Chan</signature>
          <title>Heng Fai Ambrose Chan, Director, Global Biomedical Pte. Ltd.</title>
          <date>09/02/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Alset International Limited</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Heng Fai Ambrose Chan</signature>
          <title>Heng Fai Ambrose Chan, Chief Executive Officer, Alset International Limited</title>
          <date>09/02/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
